Close Menu

NEW YORK (GenomeWeb) – Xagenic today announced it has acquired exclusive rights to a mutation detection technology developed at the University of Toronto that could be used in liquid biopsy testing.

The electrochemical clamp assay technology detects specific SNPs and genetic mutations in cell-free nucleic acids in blood plasma or serum. Xagenic said the acquisition could enable the Xagenic X1 platform to expand into blood-based or liquid biopsy testing.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.